NDLI: In Vivo Antitumor Activity of a Novel Orally Bioavailable Ifosfamide Nanostructured Lipid Carrier Against Dalton’s Ascitic Lymphoma

Please wait, while we are loading the content...

Journal of Pharmaceutical Innovation : Volume 12

Journal of Pharmaceutical Innovation : Volume 11

Journal of Pharmaceutical Innovation : Volume 10

Journal of Pharmaceutical Innovation : Volume 9

Journal of Pharmaceutical Innovation : Volume 9, Issue 4, December 2014

Journal of Pharmaceutical Innovation : Volume 9, Issue 3, September 2014

The Utilization of Quality KPIs in the Pharmaceutical Industry

A Proposed Methodology for In Vitro Evaluation of Bitterness in Drug Solutions and In Vitro Drug Release Samples

Formulation Design of Time-Controlled Release Formulation Containing Antidiabetic Drugs

In Vivo Antitumor Activity of a Novel Orally Bioavailable Ifosfamide Nanostructured Lipid Carrier Against Dalton’s Ascitic Lymphoma

Reducing Energy Consumption in Pharmaceutical Production Processes: Framework and Case Study

Glibenclamide Nanocrystals for Bioavailability Enhancement: Formulation Design, Process Optimization, and Pharmacodynamic Evaluation

Antibacterial Efficacy of Silver Nanoparticles Synthesized by a Green Method Using Bark Extract of Melia azedarach L

Formulation and Evaluation of Sustained Release Extrudes Prepared via Novel Hot Melt Extrusion Technique

Journal of Pharmaceutical Innovation : Volume 9, Issue 2, June 2014

Journal of Pharmaceutical Innovation : Volume 9, Issue 1, March 2014

Journal of Pharmaceutical Innovation : Volume 8

Journal of Pharmaceutical Innovation : Volume 7

Journal of Pharmaceutical Innovation : Volume 6

Journal of Pharmaceutical Innovation : Volume 5

Journal of Pharmaceutical Innovation : Volume 4

Journal of Pharmaceutical Innovation : Volume 3

Journal of Pharmaceutical Innovation : Volume 2

Journal of Pharmaceutical Innovation : Volume 1

In Vivo Antitumor Activity of a Novel Orally Bioavailable Ifosfamide Nanostructured Lipid Carrier Against Dalton’s Ascitic Lymphoma

Content Provider	Springer Nature Link
Author	Velmurugan, Ramaiyan Selvamuthukumar, Subramanian
Copyright Year	2014
Abstract	Ifosfamide is a widely used antineoplastic drug belonging to the alkylating agents. It is difficult to develop a conventional oral dosage form as it degrades in acidic media, with its rate of degradation depending on the pH of the solution. Thereby, ifosfamide is available either as a powder which is reconstituted with diluents for injection or as injectable solution. The present work has attempted to improve oral bioavailability of ifosfamide by incorporating in nanostructured lipid carriers (NLCs). The purpose of this research was to study whether the oral bioavailability of ifosfamide could be improved by administering ifosfamide-loaded NLCs.Ifosfamide NLCs were developed using chitosan cross-linking with sodium alginate by solvent diffusion technique. Bioavailability studies were conducted in albino rats after oral administration of ifosfamide suspension and NLC. In vivo antitumor activity of ifosfamide nanostructured lipid carrier against Dalton’s ascitic lymphoma (DAL) was also investigated.The results showed that the relative bioavailability of ifosfamide from NLC was increased by sixfold higher than that of ifosfamide suspension. Administration of ifosfamide NLC significantly decreased the tumor volume and viable cell count. Nonviable cell count was significantly higher in ifosfamide NLC-treated animals when compared with DAL control animals. Further, the median survival time was increased to 35 % on administration of ifosfamide NLC. Ifosfamide NLC significantly decreased biochemical parameters, increased the RBC count and Hb content, and reduced the WBC count as well.The results of this study show no significant difference in the antitumor efficacy of ifosfamide when administered as injection and nanoformulation. The obtained results are indicative of NLCs as potential carriers for improving the oral bioavailability and acid instability problems. The new nanoformulation would be interchangeable with the standard formulation.
Starting Page	203
Ending Page	211
Page Count	9
File Format	PDF
ISSN	18725120
Journal	Journal of Pharmaceutical Innovation
Volume Number	9
Issue Number	3
e-ISSN	19398042
Language	English
Publisher	Springer US
Publisher Date	2014-05-01
Publisher Place	Boston
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Ifosfamide Nanostructured lipid carrier Oral delivery Bioavailability In vivo antitumor activity Dalton’s ascitic lymphoma Pharmacology/Toxicology Industrial and Production Engineering Biotechnology Biochemical Engineering
Content Type	Text
Resource Type	Article
Subject	Drug Discovery Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Tailoring Apixaban in Nanostructured Lipid Carrier Enhancing Its Oral Bioavailability and Anticoagulant Activity.

ANTITUMOR ACTIVITY OF RU-PARA-CYMENE-µ-O-DICHLORIDE AGAINST DALTON’S LYMPHOMA IN VIVO AND IN VITRO

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments

In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 Against Multiple Myeloma Cells

Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus

N-acetyl-L-cysteine functionalized nanostructured lipid carrier for improving oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations

Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks

Cancer Therapy : Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 against Multiple Myeloma Cells

In Vivo Antitumor Activity of a Novel Orally Bioavailable Ifosfamide Nanostructured Lipid Carrier Against Dalton’s Ascitic Lymphoma

Similar Documents

Tailoring Apixaban in Nanostructured Lipid Carrier Enhancing Its Oral Bioavailability and Anticoagulant Activity.

ANTITUMOR ACTIVITY OF RU-PARA-CYMENE-µ-O-DICHLORIDE AGAINST DALTON’S LYMPHOMA IN VIVO AND IN VITRO

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Development and optimization of sulforaphane-loaded nanostructured lipid carriers by the Box-Behnken design for improved oral efficacy against cancer: in vitro, ex vivo and in vivo assessments

In vitro and In vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 Against Multiple Myeloma Cells

Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus

N-acetyl-L-cysteine functionalized nanostructured lipid carrier for improving oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations

Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks

Cancer Therapy : Preclinical In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN 9708 against Multiple Myeloma Cells

In Vivo Antitumor Activity of a Novel Orally Bioavailable Ifosfamide Nanostructured Lipid Carrier Against Dalton’s Ascitic Lymphoma